Concord Drugs, a company in the Pharmaceuticals industry, reported revenue of ₹42 crore and net profit of ₹2.21 crore for the September 2026 quarter.
Concord Drugs (BSE: CONCORD) closed at ₹68.87 on 20 Nov 2026, down 15.3% over the past year. Its market capitalisation is ₹91 crore and it trades at 30.7 times earnings.
Incorporated in 1995, Concord Drugs Ltd manufactures licensed drugs based on approved formulations
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.